Tyrosine Protein Kinase Receptor Tyro3

Introduction

TYRO3 (Tyrosine-protein kinase receptor TYRO3) is a member of the TAM (Tyro3, Axl, Mer) family of receptor tyrosine kinases. These receptors play crucial roles in diverse cellular processes by transducing extracellular signals into intracellular responses. TYRO3, along with its family members, is activated by binding to its ligands, primarily Growth Arrest-specific 6 (GAS6) and Protein S. This binding initiates a signaling cascade that influences cell survival, proliferation, differentiation, and the clearance of apoptotic cells through a process known as efferocytosis.

Biological Basis

At a molecular level, TYRO3 is a transmembrane protein with an extracellular ligand-binding domain, a single transmembrane helix, and an intracellular tyrosine kinase domain. Upon ligand binding, TYRO3 dimerizes and undergoes autophosphorylation on specific tyrosine residues within its intracellular domain. These phosphorylated tyrosines serve as docking sites for various intracellular signaling molecules, leading to the activation of downstream pathways such as the PI3K/Akt and MAPK pathways. These pathways regulate critical cellular functions, including gene expression, metabolism, and cytoskeletal rearrangements.

Clinical Relevance

Dysregulation of TYRO3 signaling has been implicated in a variety of human diseases. Its roles in cell survival and proliferation make it a factor in cancer development and progression, where it can promote tumor growth, metastasis, and resistance to therapy. Furthermore, TYRO3 contributes to immune system modulation, and its altered activity is associated with autoimmune disorders and chronic inflammation. In the nervous system, TYRO3 is involved in neuronal development, synaptic plasticity, and the phagocytosis of neuronal debris, suggesting potential links to neurodegenerative diseases.

Understanding the intricate functions of TYRO3 and its signaling pathways holds significant social importance, particularly in the context of therapeutic development. As a receptor tyrosine kinase, TYRO3 represents a potential target for novel drug therapies aimed at treating cancers, autoimmune conditions, and neurological disorders. Research into TYRO3 and its genetic variations can provide insights into disease mechanisms, aid in the identification of biomarkers for diagnosis and prognosis, and pave the way for personalized medicine approaches.

Variants

The Variants section explores genetic variations and their associated genes, highlighting their potential influence on biological processes, particularly those relevant to tyrosine protein kinase receptor TYRO3. These variants, identified across several genes, play diverse roles in cellular signaling, gene expression, metabolism, and structural integrity, all of which can collectively impact health and disease.

The TYRO3 gene, encoding a receptor tyrosine kinase, is critical for various cellular functions, including cell survival, differentiation, and immune responses, by mediating complex signaling pathways. Variants such as rs4924560, rs28830273, and rs141886991 are located within the genomic region encompassing TYRO3 and MGA. MGA (Max Gene Associated protein) acts as a transcription factor, often repressing Myc target genes, thereby influencing cell cycle progression and differentiation. These variants could potentially modulate the intricate interplay between TYRO3-mediated signaling and MGA-regulated gene expression, impacting cellular growth, survival, and immune processes. Furthermore, variants rs11639399 and rs141669463 specifically within the TYRO3 gene may directly alter the protein's structure or expression, influencing its kinase activity or ligand binding, which are critical for its diverse biological functions. ^[1]

The ABO gene is fundamental in determining human blood groups through its glycosyltransferase activity, which modifies cell surface antigens. ^[2] Variants rs2519093 and rs8176671 within ABO can influence blood type and have been associated with various health outcomes, including plasma levels of liver enzymes and inflammatory markers. ^[3] The region also includes variants like rs78590974 and rs72775457 associated with Y_RNA, a class of small non-coding RNAs involved in RNA processing and quality control. These variants, by affecting ABO glycosyltransferase activity or Y_RNA function, could indirectly impact cellular recognition, inflammatory responses, and overall physiological homeostasis, which might intersect with pathways regulated by TYRO3.

Several other genes involved in fundamental cellular processes also harbor notable variants. The RPAP1 (RNA Polymerase II Associated Protein 1) gene plays a role in gene transcription by interacting with RNA polymerase II, influencing the overall landscape of gene expression. Variants rs117378653, rs117391509, rs7163686, rs77277118, and rs2588323 associated with RPAP1 (and nearby pseudogene ELOCP2) could modify transcriptional efficiency or stability, thereby affecting the production of various proteins, including those involved in TYRO3 signaling. Similarly, RTF1 (RTF1, Paf1 Homolog, Transcription Elongation Factor) (rs62001419) is a component of the Paf1 complex, critical for transcription elongation, histone modifications, and RNA processing. ^[1] Variants affecting these transcription regulators can have broad effects on cellular function, and thus indirectly on TYRO3 pathways. SPTBN5 (Spectrin Beta, Non-Erythrocytic 5) (rs28674949) contributes to the spectrin cytoskeleton, essential for maintaining cell shape, membrane integrity, and intracellular transport, where alterations could impact cell surface receptor presentation and signaling, including that of TYRO3.

The ASGR1 (Asialoglycoprotein Receptor 1) gene, with variant rs186021206, is primarily expressed in the liver, where it is responsible for the rapid clearance of circulating asialoglycoproteins. ^[1] This receptor plays a crucial role in maintaining hepatic homeostasis and regulating systemic glycoprotein levels. Changes introduced by rs186021206 could affect liver function and the metabolism of various circulating factors, potentially influencing the broader physiological environment and indirectly impacting cellular communication pathways like those involving TYRO3. RPL7AP64 (Ribosomal Protein L7a Pseudogene 64), a pseudogene in the vicinity, might have regulatory roles, such as influencing the expression of its functional counterpart or other genes through non-coding RNA mechanisms.

Key Variants

RS ID	Gene	Related Traits
rs4924560 rs28830273 rs141886991	TYRO3 - MGA	tyrosine-protein kinase receptor TYRO3 measurement
rs2519093 rs8176671	ABO	coronary artery disease venous thromboembolism hemoglobin measurement hematocrit erythrocyte count
rs117378653 rs117391509 rs7163686	RPAP1	tyrosine-protein kinase receptor TYRO3 measurement
rs117834187 rs369802578 rs181337989	MGA	tyrosine-protein kinase receptor TYRO3 measurement
rs186021206	RPL7AP64 - ASGR1	ST2 protein measurement alkaline phosphatase measurement low density lipoprotein cholesterol measurement, lipid measurement low density lipoprotein cholesterol measurement low density lipoprotein cholesterol measurement, phospholipid amount
rs11639399 rs141669463	TYRO3	tyrosine-protein kinase receptor TYRO3 measurement
rs77277118 rs2588323	RPAP1 - ELOCP2	tyrosine-protein kinase receptor TYRO3 measurement
rs28674949	SPTBN5	tyrosine-protein kinase receptor TYRO3 measurement
rs62001419	RTF1	tyrosine-protein kinase receptor TYRO3 measurement
rs78590974 rs72775457	ABO - Y_RNA	angiotensin-converting enzyme measurement basigin measurement level of carcinoembryonic antigen-related cell adhesion molecule 20 in blood tgf-beta receptor type-2 measurement vascular endothelial growth factor receptor 3 amount

Pathways and Mechanisms

Tyrosine protein kinase receptors, such as TYRO3, are key mediators of cellular signaling, influencing a wide range of biological processes. The following sections detail various pathways and mechanisms that exemplify how such receptors integrate metabolic, regulatory, and systemic functions, drawing from broader biological contexts presented in the research.

Receptor-Mediated Signal Transduction

Receptor tyrosine kinases are central to initiating intracellular signaling cascades upon activation, translating extracellular cues into cellular responses. A prominent example of such a cascade is the Mitogen-Activated Protein Kinase (MAPK) pathway, which is activated in human skeletal muscle, influencing cellular processes in response to factors like age and acute exercise. ^[4] This pathway's regulation is complex, with proteins like tribbles controlling MAPK cascades, highlighting the intricate feedback and feedforward loops inherent in signal transduction. ^[5] The activation of these cascades ultimately leads to the regulation of various cellular functions, including proliferation, differentiation, and survival.

Further downstream from these initial cascades, intracellular signaling often converges on the activation or repression of transcription factors. For instance, transcription factors like MEF2C (Myocyte Enhancer Factor 2C) are critical for cardiac morphogenesis and myogenesis ^[6] and their dysregulation can lead to conditions such as dilated cardiomyopathy. ^[7] Similarly, HNF1A (Hepatocyte Nuclear Factor 1 Alpha) plays a role in regulating gene expression, including the synergistic trans-activation of the human C-reactive protein promoter. ^[8] These examples demonstrate how receptor-mediated signals can profoundly impact gene expression programs, thereby dictating cell fate and function.

Metabolic Homeostasis and Regulation

Receptor tyrosine kinases are deeply intertwined with the regulation of metabolic pathways, influencing energy metabolism, biosynthesis, and catabolism. Lipid metabolism is particularly subject to such regulation, with factors like Angiopoietin-like protein 4 (ANGPTL4) acting as a potent hyperlipidemia-inducing factor and an inhibitor of lipoprotein lipase, affecting triglyceride levels . ^{[9], [10]} Common genetic variants in loci such as ANGPTL3 and HMGCR (3-hydroxy-3-methylglutaryl coenzyme A reductase) are associated with plasma lipid concentrations, including LDL-cholesterol and triglycerides, reflecting their roles in the mevalonate pathway and overall lipid biosynthesis . ^{[11], [12], [13], [14]} The Sterol Regulatory Element Binding Protein-2 (SREBP-2) transcription factor also links isoprenoid and adenosylcobalamin metabolism, demonstrating broad metabolic regulation. ^[15]

Glucose metabolism is another critical area influenced by these pathways, with genes like glucokinase playing a vital role in regulating glucose activity, and mutations affecting its function linked to conditions like Maturity-Onset Diabetes of the Young (MODY2). ^[16] The 5'-AMP-activated protein kinase (PRKAG2) is an enzyme that modulates glucose uptake and glycolysis, and its mutations are associated with glycogen storage in cardiomyocytes and cardiac hypertrophy . ^{[17], [18]} Furthermore, the SLC2A9 gene encodes a urate transporter that influences serum uric acid concentration, highlighting the diverse metabolic processes under regulatory control . ^{[19], [20]}

Gene Expression and Post-Translational Control

The precise control of gene expression is a fundamental regulatory mechanism, often orchestrated by transcription factors whose activity can be modulated by upstream signaling pathways. For instance, HNF1A mutations impact age at diabetes diagnosis in MODY3 patients, and genetic variability at the leptin receptor (LEPR) locus is a determinant of plasma fibrinogen and C-reactive protein levels, demonstrating the transcriptional control over metabolic and inflammatory markers . ^{[3], [21], [22]} The transcription factor 7-like 2 (TCF7L2) gene variants also confer risk of type 2 diabetes, further illustrating the role of transcriptional regulation in disease susceptibility . ^{[23], [24]}

Beyond gene expression, proteins themselves are subject to extensive post-translational modifications that finely tune their activity, localization, and interactions. Phosphorylation, a hallmark of tyrosine protein kinase activity, serves as a rapid and reversible switch for protein function. This type of regulation can impact enzyme activity, such as the functional analysis of glucokinase gene mutations revealing regulatory mechanisms of its activity. ^[16] Such modifications allow for dynamic control over cellular processes, complementing the slower changes mediated by transcriptional regulation.

Inter-Pathway Crosstalk and Systemic Integration

Cellular pathways do not operate in isolation but rather form complex networks through extensive crosstalk and hierarchical regulation, leading to emergent properties at the systems level. The interaction between LEPR and HNF1A pathways, for instance, influences plasma C-reactive protein levels, indicating a confluence of metabolic and inflammatory signaling . ^{[21], [25]} Similarly, during cardiac hypertrophy, parallel gene expressions of IL-6 and Brain Natriuretic Peptide (BNP) are observed, suggesting an integrated response involving inflammatory cytokines and cardiac stress markers. ^[26]

This systems-level integration extends to the cardiovascular system, where neuronal chemorepellent Slit2 inhibits vascular smooth muscle cell migration by suppressing small GTPase Rac1 activation, illustrating crosstalk between nervous system cues and vascular biology. ^[27] Angiotensin II also increases phosphodiesterase 5A expression in vascular smooth muscle cells, providing a mechanism by which it antagonizes cGMP signaling and influences vascular tone. ^[28] These examples highlight how diverse molecular signals are integrated to maintain physiological homeostasis and respond to various stimuli across different organ systems.

Disease Mechanisms and Therapeutic Implications

Dysregulation within these intricate pathways is frequently implicated in the development and progression of various diseases, offering potential targets for therapeutic intervention. For instance, common variants at multiple loci contribute to polygenic dyslipidemia, a condition characterized by abnormal lipid levels and increased risk of coronary artery disease . ^{[12], [13]} Hypertriglyceridemia, linked to diminished very low-density lipoprotein fractional catabolic rates, exemplifies how specific metabolic pathway alterations contribute to disease. ^[29]

In cardiac health, mutations in the cardiac ryanodine receptor gene (RYR2) underlie catecholaminergic polymorphic ventricular tachycardia and are implicated in exercise-induced tachyarrhythmias, demonstrating how ion channel dysregulation leads to severe cardiac conditions . ^{[17], [30], [31]} Similarly, mutations in PRKAG2 are associated with glycogen-filled vacuoles in cardiomyocytes, leading to cardiac hypertrophy and Wolff-Parkinson-White syndrome . ^{[17], [18]} Understanding these precise molecular mechanisms of pathway dysregulation provides critical insights for identifying compensatory mechanisms and developing targeted therapeutic strategies for conditions ranging from metabolic disorders like type 2 diabetes to complex cardiovascular diseases . ^{[16], [32]}

References

[1] Wilk, J. B., et al. "Framingham Heart Study genome-wide association: results for pulmonary function measures." BMC Med Genet, vol. 8, no. Suppl 1, 2007, p. S8.

[2] Melzer, D., et al. "A genome-wide association study identifies protein quantitative trait loci (pQTLs)." PLoS Genet, vol. 4, no. 5, 2008, p. e1000072.

[3] Yuan, X., et al. "Population-based genome-wide association studies reveal six loci influencing plasma levels of liver enzymes." Am J Hum Genet, 2008, 83(4):520-8.

[4] Williamson, D., et al. "Mitogen-activated protein kinase (MAPK) pathway activation: effects of age and acute exercise on human skeletal muscle." J Physiol, 2003, 547:977-987.

[5] Kiss-Toth, E., et al. "Human tribbles, a protein family controlling mitogen-activated protein kinase cascades." J Biol Chem, 2004, 279:42703–42708.

[6] Lin, Q., Schwarz, J., Bucana, C., and Olson, E.N. "Control of mouse cardiac morphogenesis and myogenesis by transcription factor MEF2C." Science, 1997, 276:1404-1407.

[7] Xu, J., et al. "Myocyte enhancer factors 2A and 2C induce dilated cardiomyopathy in transgenic mice." J Biol Chem, 2006, 281:9152-9162.

[8] Toniatti, C., et al. "Synergistic trans-activation of the human C-reactive protein promoter by transcription factor HNF-1 binding at two distinct sites." EMBO J., 1990, 9:4467–4475.

[9] Yoshida, K., et al. "Angiopoietin-like protein 4 is a potent hyperlipidemia-inducing factor in mice and inhibitor of lipoprotein lipase." J. Lipid Res., 2002, 43:1770–1772.

[10] Romeo, S., et al. "Population-based resequencing of ANGPTL4 uncovers variations that reduce triglycerides and increase HDL." Nat Genet, 2007, 39:513–516.

[11] Burkhardt, R., et al. "Common SNPs in HMGCR in micronesians and whites associated with LDL-cholesterol levels affect alternative splicing of exon13." Arterioscler Thromb Vasc Biol, 2008, 28(10):1892-9.

[12] Kathiresan, S. "Common variants at 30 loci contribute to polygenic dyslipidemia." Nat Genet, 2008, 40(12):1492-7.

[13] Willer, C.J., et al. "Newly identified loci that influence lipid concentrations and risk of coronary artery disease." Nat Genet, 2008, 40(1):161-9.

[14] Goldstein, J.L., and Brown, M.S. "Regulation of the mevalonate pathway." Nature, 1990, 343:425–430.

[15] Murphy, C., et al. "Regulation by SREBP-2 defines a potential link between isoprenoid and adenosylcobalamin metabolism." Biochem Biophys Res Commun, 2007, 355:359–364.

[16] Garcia-Herrero, C.M., et al. "Functional analysis of human glucokinase gene mutations causing MODY2: exploring the regulatory mechanisms of glucokinase activity." Diabetologia, 2007, 50:325–333.

[17] Vasan, R.S. "Genome-wide association of echocardiographic dimensions, brachial artery endothelial function and treadmill exercise responses in the Framingham Heart Study." BMC Med Genet, 2007, 8(Suppl 1):S2.

[18] Gollob, M.H., et al. "Identification of a gene responsible for familial Wolff-Parkinson-White syndrome." N Engl J Med, 2001, 344:1823-1831.

[19] Vitart, V., et al. "SLC2A9 is a newly identified urate transporter influencing serum urate concentration, urate excretion and gout." Nat Genet, 2008, 40(4):432-7.

[20] Gieger, C., et al. "Genetics meets metabolomics: a genome-wide association study of metabolite profiles in human serum." PLoS Genet, 2008, 4(11):e1000282.

[21] Zhang, Y.Y., et al. "Genetic variability at the leptin receptor (LEPR) locus is a determinant of plasma ﬁbrinogen and C-reactive protein levels." Am J Hum Genet, 2007, 81(6):1185-92.

[22] Reiner, A.P., et al. "Polymorphisms of the HNF1A gene encoding hepatocyte nuclear factor-1 alpha are associated with C-reactive protein." Am J Hum Genet, 2008, 82(5):1185-92.

[23] Grant, S.F., et al. "Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes." Nat Genet, 2006, 38(3):320-3.

[24] Meigs, J.B., et al. "Genome-wide association with diabetes-related traits in the Framingham Heart Study." BMC Med Genet, 2007, 8(Suppl 1):S15.

[25] Ridker, P.M. "Loci related to metabolic-syndrome pathways including LEPR,HNF1A, IL6R, and GCKR associate with plasma C-reactive protein: the Women's Genome Health Study." Am J Hum Genet, 2008, 82(5):1182-90.

[26] Haugen, E., et al. "Parallel gene expressions of IL-6 and BNP during cardiac hypertro-phy complicated with diastolic dysfunction in spontaneously hypertensive rats." Int J Cardiol, 2006, 114(2):211-7.

[27] Liu, D., et al. "Neuronal chemorepellent Slit2 inhibits vascular smooth muscle cell migration by suppressing small GTPase Rac1 activation." Circ Res, 2006, 98:480-489.

[28] Kim, D., et al. "Angiotensin II increases phosphodiesterase 5A expression in vascular smooth muscle cells: a mechanism by which angiotensin II antagonizes cGMP signaling." J Mol Cell Cardiol, 2005, 38:175-184.

[29] Aalto-Setala, K., et al. "Mechanism of hypertriglyceridemia in human apolipoprotein (apo) CIII transgenic mice. Diminished very low density lipoprotein fractional catabolic rate associated with increased apo CIII and reduced apo E on the particles." J. Clin. Invest., 1992, 90:1889–1900.

[30] Benkusky, N.A., Farrell, E.F., and Valdivia, H.H. "Ryanodine receptor channelopathies." Biochem Biophys Res Commun, 2004, 322:1280-1285.

[31] Priori, S.G., et al. "Mutations in the Cardiac Ryanodine Receptor Gene (hRyR2) Underlie Catecholaminergic Poly-Ventricular Tachycardia." Circulation, 2001, 103:196-200.

[32] Chalasani, N., et al. "Glycosylphosphatidylinositol-speciﬁc phospholipase d in nonalcoholic Fatty liver disease: A preliminary study." J. Clin. Endocrinol. Metab., 2006, 91:2279–2285.